Neurology
From the Journals
Mindfulness yoga reduced stress and motor symptoms in patients with Parkinson’s disease
Yoga was as effective as conventional exercise in improving motor function in patients with Parkinson’s disease.
News from the FDA/CDC
FDA concerned about e-cigs/seizures in youth
Between 2010 and early 2019, the FDA and poison control centers received 35 reports of seizures that mentioned the use of e-cigarettes
From the Journals
Rituximab does not improve fatigue symptoms of ME/CFS
Results from the phase 3 RituxME trial found no difference in fatigue score symptoms after 24 months.
News from the FDA/CDC
FDA approves Mavenclad for treatment of relapsing MS
Cladribine (Mavenclad) is the first short-course oral therapy for adult patients with relapsing/remitting or active secondary progressive MS.
From the Journals
Valproate, topiramate prescribed in young women despite known teratogenicity risks
These findings suggest a lack of awareness of the teratogenic risks of valproate and topiramate on the part of physicians and patients.
News from the FDA/CDC
FDA approves siponimod for relapsing forms of MS
The oral treatment reduces the risk of 3-month confirmed disability progression and may improve cognition and MRI disease activity.
Conference Coverage
Study launched to further evaluate the central vein sign in MS
DALLAS – A total of 10 clinical sites in North America are participating, with the Cleveland Clinic coordinating.
Feature
Report calls for focus on ‘subpopulations’ to fight opioid epidemic
“Methadone, buprenorphine, and extended-release naltrexone ... save lives” but most people with OUD get no treatment, new report says.
From the Journals
Surge of gabapentinoids for pain lacks supporting evidence
Review of 54 papers for gabapentin and 30 for pregabalin finds little evidence for effective pain control in off-label uses.
Conference Coverage
Intensive blood pressure lowering may not reduce risk of recurrent stroke
HONOLULU – Intensive treatment significantly reduces blood pressure, compared with standard treatment, and is...
Conference Coverage
Genetic signature helps identify those at risk of MS
DALLAS – “In this effort to redefine this disease and when it starts, these molecular and cellular studies are becoming very important.”